Four parties report shared voting power in Fortress Biotech (FBIO)'s ownership amendment.

Fortress Biotech (FBIO) Slips 1.17% to $2.11 as Shares Drift Toward $2.00 Support - Sign of Weakness

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech Q2 Earnings Call Highlights

Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy

FBIO Forecast — Price Target — Prediction for 2027

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower

symbol__ Stock Quote Price and Forecast